Fascin-1 is a novel biomarker of aggressiveness in some carcinomas

BMC Medicine

Eleftherios P Diamandis¹  Vathany Kulasingam² 

[1] Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Mount Sinai Hospital, 60 Murray Street, Toronto, ON, M5T 3L9, Canada;Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada

关键词: tumor markers;    prognosis;    immunohistochemistry;    fascin-1;    diagnosis;   

Others  :  857169
DOI  :  10.1186/1741-7015-11-53

 received in 2013-02-05, accepted in 2013-02-26,  发布年份 2013

【 摘 要 】

Tremendous progress has been made in recent years towards the understanding, prevention and management of malignant disease, yet cancer remains a leading cause of global mortality and morbidity. Current approaches towards combating this disease include prevention, early detection and various treatment modalities. However, even with implementation of novel therapeutic options and preventative measures, most cancers are currently diagnosed at late stages, when treatment therapies are least effective. In a recent study published in BMC Medicine, Tan et al. performed a systematic review and meta-analysis to show that fascin-1, an actin-bundling protein, is associated with increased risk of mortality and metastasis in various cancer types. Although the study examined the association of fascin-1 with mortality, time-to-disease progression, lymph node metastasis and distant metastasis in five major cancer types, the clinical implications of these findings are still unclear and many unanswered questions remain.

Please see related research article here http://www.biomedcentral.com/1741-7015/11/52 webcite

【 授权许可】

   
2013 Kulasingam and Diamandis; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. [http://globocan.iarc.fr] webciteLyon, France: International Agency for Research on Cancer; 2010.
• [2]Siegel R, Naishadham D, Jemal A: Cancer Statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
• [3]Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L: The case for early detection. Nat Rev Cancer 2003, 3:243-252.
• [4]Tan VY, Lewis SJ, Adams JC, Martin RM: Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Medicine 2013, 11:52. BioMed Central Full Text
• [5]Hashimoto Y, Kim DJ, Adams JC: The role of fascins in health and disease. J Pathol 2011, 224:289-300.
• [6]Hashimoto Y, Skacel M, Adams J: Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 2005, 37:1787-804.
• [7]Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC: Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer 2006, 6:241. BioMed Central Full Text
• [8]Diamandis EP: The failure of protein cancer biomarkers to reach the clinic: Why and what can be done to address the problem? BMC Med 2012, 10:87. BioMed Central Full Text